TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06259669: Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Popul

Sponsor: Incyte Corporation · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 958 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$8,256,000

Rescue Site Savings

+$5,443,800

Unlock Full NCT06259669 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06259669 Rescue Dossier →